# Claude Opus 5 — deep_reasoning/ethical_dilemma_structured

- model_id: `anthropic/claude-opus-5`
- success: True  | final: 8.1 | quality: 10.0
- latency_total: 31.706s | tokens_per_second: 64.6
- input_tokens: 304 | output_tokens: 2048

## Entrada exacta (lo que recibió el modelo)

**user:**

Una startup de IA tiene un modelo que puede detectar cancer con 95% de precision.
Sin embargo:
- El 5% de falsos positivos causa ansiedad severa y procedimientos innecesarios
- El modelo funciona peor en personas de piel oscura (90% precision vs 97% en piel clara)
- Lanzar ahora salvaria vidas pero con sesgo conocido
- Esperar 6 meses para corregir el sesgo significa que gente morira mientras tanto

El board te pide una recomendacion. Estructura tu analisis:
1. Identifica a todos los stakeholders afectados
2. Analiza los trade-offs cuantitativamente
3. Proporciona 3 opciones con pros/contras de cada una
4. Da tu recomendacion final con justificacion

No busques la respuesta "correcta" - busca la mejor argumentada.


## Respuesta completa

I need to build a rigorous quantitative model for this analysis, being careful to distinguish between sensitivity, specificity, and positive predictive value since "95% precision" is ambiguous without knowing the base rate and which metric it actually refers to. I'll develop three distinct options with clear assumptions and then provide a final recommendation backed by the math.

Let me work through a concrete screening scenario with specific numbers. Assuming a 0.5% cancer prevalence in the screening population, 95% sensitivity, and 95% specificity, I can calculate that out of 100,000 people screened, there would be roughly 475 true detections but also 4,975 false positives—giving a positive predictive value of only 8.7%, meaning about 10 false alarms per true detection. This is actually typical for screening programs like mammography.

Now examining the bias: if the model achieves 90% sensitivity in dark-skinned populations versus 97% in light-skinned populations, that translates to roughly 35 excess missed cancers per 100,000 screened in the darker-skinned group. With mortality attributable to missed detection around 30-50% of those cases, I'm looking at approximately 10-17 excess deaths per 100,000 in the affected population. But the key question is what the counterfactual actually is—not a perfect system, but the current standard of care, which for darker-skinned populations already involves worse dermatologist access and later-stage melanoma diagnoses.

The real tension is between deployment harms and non-deployment harms. Deploying risks entrenchment and false reassurance, but withholding a 90%-accurate tool when the status quo is substantially worse may itself cause harm. I'm weighing a staged conditional launch with per-group threshold recalibration to equalize sensitivity, mandatory human oversight for the higher-risk subgroup, and a concrete commitment to parallel bias remediation—essentially trading specificity for sensitivity in the darker-skinned population to level the detection rates.

But I need to be honest about the limits: if the performance gap is driven by discrimination in the underlying data rather than just threshold effects, lowering thresholds can equalize sensitivity only at the cost of more false positives. I'm also mapping out the stakeholder landscape—patients, clinicians, hospital systems, regulators (FDA classification matters here), payers, and the data subjects needed for the remediation work itself—to ensure informed consent and accountability across the board.

The "6 months" timeline deserves scrutiny too. ML projects slip regularly, and sourcing dermatology images from darker skin tones has historically been a bottleneck, so the actual probability of achieving parity in that window is probably closer to 40%. The waiting cost is real—excess deaths across all groups—but the math gets more nuanced when I account for the fact that regulatory clearance alone takes at least 6 months, and real-world adoption ramps over 12-24 months anyway. That reframes the dilemma as potentially less stark than it first appears. I'm going to work through a comparison with concrete numbers on excess deaths and equity gaps.

Now I'm setting up the calculation with specific assumptions about the addressable population, cancer prevalence, adoption ramp, baseline sensitivity differences between skin tones, and how missed detections convert to mortality.

For light-skinned populations, the model achieves 97% sensitivity versus an 85% baseline, preventing about 480 missed cases and averting roughly 192 deaths annually. For…